Hong Kong’s AI drug discovery firm Insilico closes $60M Series D

Insilico Medicine, a Hong Kong-based company that has been using artificial intelligence to discover new drugs since 2014, has completed a fresh round of funding.
It’s a sign that certain investors are continuing to bet on emerging biotechnologies — which often take longer to prove profitability compared to other verticals — at a time venture funding is cooling.
Insilico raised $60 million from a new Serie D financing from investors including its existing shareholders Warburg Pincus, B Capital, Qiming Venture Partners, BOLD Capital Partners, Pavilion Capital, and new investor

リンク元